Seeing Is Believing
Currently out of the existing stock ratings of Keay Nakae, 123 are a BUY (82%), 19 are a HOLD (12.67%), 8 are a SELL (5.33%).
Analyst Keay Nakae works at CHARDAN CAPITAL with a stock forecast success ratio of 44.44% fulfilled within 104.24 days on average.
Keay Nakae’s has documented 264 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SABS, SAB Biotherapeutics at 02-Apr-2024.
Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/8/2021. The price target of $13 was fulfilled within 1 day with a profit of $2.81 (17.77%) receiving and performance score of 177.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
4
$1.25 (45.45%)
4
21 days ago
0/5 (0%)
$1 (33.33%)
Buy
4
$1.25 (45.45%)
6
1 months 24 days ago
1/8 (12.5%)
$1.21 (43.37%)
139
Buy
5
$2.25 (81.82%)
6
1 months 24 days ago
0/13 (0%)
$2.21 (79.21%)
Buy
5
$2.08 (71.23%)
2 years 2 months 23 days ago
0/1 (0%)
$2.11 (73.01%)
Buy
7
2 years 9 months 28 days ago
0/4 (0%)
$3.7 (112.12%)
Which stock is Keay Nakae is most bullish on?
Which stock is Keay Nakae is most reserved on?
What Year was the first public recommendation made by Keay Nakae?